Alto Neuroscience Inc (ANRO) - News Archive

Enhancing the field of neuropsychiatric treatment is paramount in addressing the growing global mental health crisis. This article explores the recent $50 million private placement financing by Alto Neuroscience, a clin...

In the ever-evolving landscape of biotechnology and pharmaceuticals, the spotlight often shines brightly on companies that promise innovative solutions to pressing health challenges. Alto Neuroscience, Inc., a biotech f...

: The pharmaceutical industry, characterized by its rapid advancements and critical role in healthcare, demands transparency and accuracy in the dissemination of information. Recent legal challenges faced by Alto Neuros...

The Crucial Deadline for Alto Neuroscience Investors: A Call to Action from Rosen Law FirmIn a world where the stock market constantly fluctuates, investors in Alto Neuroscience, Inc. (NYSE: ANRO) face a pivotal moment....

Alto Neuroscience: Progress Amidst Challenges at the 63rd Annual ACNP MeetingAlto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company dedicated to the development of innovative precision medicine...

Alto Neuroscience Unveils Revelatory Publication: Baseline Cognitive Performance Does Not Influence Antidepressant Efficacy Mountain View, Calif. In an era where the elucidation of neuropsychiatric maladies remains para...

Is Palo Alto Networks the Best Cybersecurity Stock to Buy Now In today s sell-off of Alto Neuroscience Inc shares, investors are left questioning their choices and seeking alternative investment opportunities. The recen...

Mountain View, Calif. - Alto Neuroscience, a clinical-stage biopharmaceutical company dedicated to developing pioneering precision medicines for neuropsychiatric disorders, proudly announces the successful completion of...

Alto Neuroscience Ventures into Phase 2 Study of ALTO-101: A Groundbreaking Treatment for Cognitive Impairment in Schizophrenia LOS ALTOS, Calif. - Alto Neuroscience, a leading biotech company, has recently launched a p...

Alto Neuroscience Announces Robust Q1 2024 Financial Results and Impressive Pipeline Progress LOS ALTOS, Calif. Amid the dynamic landscape of biopharmaceutical innovations, Alto Neuroscience, Inc. (NYSE: ANRO) recently...

Alto Neuroscience, a prominent player in the field of precision psychiatry, has recently showcased its late-stage clinical pipeline and robust platform through a series of data presentations at the upcoming Society of B...

Alto Neuroscience Bolsters Leadership Team with Addition of Dr. Maha RadhakrishnanLOS ALTOS, Calif. – Alto Neuroscience, a leading innovator in the neurotechnology space, is pleased to announce the appointment of Dr. Ma...

Alto Neuroscience Prices Upsized IPO, Raises Approximately $128.6 MillionAlto Neuroscience, a California-based neuroscience company (NYSE: ANRO), announced the pricing of its upsized initial public offering (IPO) today....